To examine the reliability and convergent validity of the Japanese version of the Athlete Sleep Screening Questionnaire (ASSQ) in Japanese elite athletes across a wide range of ages and competition levels, including high-school athletes and national- and international-level competitors. A total of 139 elite Japanese athletes, including 41 high-school athletes, completed the ASSQ, Pittsburgh Sleep Quality Index (PSQI), and Insomnia Severity Index (ISI), and 133 repeated the ASSQ after 1–2 weeks. Internal consistency was assessed using Cronbach’s alphas. Test–retest reliability was evaluated using intraclass correlation coefficients (ICC) and Cohen’s kappa. Convergent validity was examined using Pearson’s correlations and cutoff-level agreement. Moderate-to-severe sleep difficulty (SDS ≥ 8) was identified in 28.8
To investigate the differences in metabolic profiles between patients with narcolepsy type 1 (NT1) and controls, and to examine the specific associations of uric acid (UA), atherogenic index of plasma (AIP), and body mass index (BMI) with rapid eye movement (REM) sleep “initiation” and “maintenance,” as well as their severity-dependent patterns across severity stages. 50 NT1 patients and 50 controls were enrolled to compare lipid metabolism and inflammatory markers. Overnight polysomnography was performed on the NT1 group. Logistic regression identified independent risk factors for NT1. A partial correlation matrix was constructed to progressively control for confounders and analyze correlations between metabolic indices and REM frequency/rem sleep maintenance index. Logistic regression models for different dimensions and severities of REM impairment were built using leave-one-out cross-validation nested with Bayesian Information Criterion (BIC) stepwise regression. Decision curve analysis evaluated clinical net benefit. NT1 group exhibited significantly elevated AIP, triglycerides, and UA (all p <0.05). AIP and UA were independent risk factors for NT1 (odds ratio, OR = 7.354, p < 0.001; OR = 1.021, p < 0.001). Partial correlation analysis showed that the negative correlation between UA and REM frequency was independent of BMI (partial ρ = −0.338, p = 0.023); the association between AIP and REM maintenance index disappeared after controlling for BMI; the negative effect of BMI on REM initiation completely attenuated after controlling for UA (partial ρ = −0.141, p = 0.355). Predictive models revealed a dynamic evolution of dominant variables: UA was consistently selected (100
To systematically evaluate and rank the effects of non-pharmacological interventions on sleep quality in patients with chronic heart failure, to inform clinical sleep management. PubMed, Web of Science, the Cochrane Library, CINAHL, Embase, China National Knowledge Infrastructure, WanFang, VIP, and the Chinese Biomedical Literature Database were searched from inception to May 2026. Two reviewers independently screened studies, extracted data, and assessed risk of bias. Post−intervention Pittsburgh Sleep Quality Index (PSQI) scores or change−from−baseline scores were synthesised using a Bayesian random−effects network meta−analysis. Treatment rankings were summarised using the surface under the cumulative ranking curve (SUCRA). The protocol was registered in PROSPERO (CRD420261340525). Twenty randomised controlled trials involving 2,120 participants formed an eight−node network. Compared with usual care, psychological/behavioural interventions (MD − 4.24, 95
The aim of this study was to identify anthropometric predictors of early OSA resolution after bariatric surgery (BS). Patients with OSA treated with APAP for at least one month before BS underwent anthropometric assessments and home polygraphy at baseline and 2 (and 6) months postoperatively. Among 18 patients, all anthropometric measures improved significantly, while OSA resolution increased from 56
To investigate the effects of vornorexant, a novel dual orexin receptor antagonist developed for the treatment of insomnia, on patient-reported sleep status and daytime functioning in a randomized, double-blinded, placebo-controlled pivotal phase 3 trial. A total of 589 patients were administered placebo, vornorexant 5 mg, or vornorexant 10 mg in a 1:1:1 ratio for 2 weeks. The patients completed the Insomnia Severity Index (ISI), Sheehan Disability Scale (SDS), and Leeds Sleep Evaluation Questionnaire (LSEQ) as secondary endpoints. Both vornorexant 5 mg and 10 mg significantly improved total and daytime functioning scores of the ISI, SDS, and subsets of getting to sleep, quality of sleep, and behavior following wakefulness of LSEQ, compared with the placebo. However, the subsets of awakening from sleep did not demonstrate significant differences between the groups. Vornorexant was well tolerated throughout the study. These results support the beneficial effects of vornorexant on subjective sleep status and daytime functioning as assessed by using standardized subjective assessment tools in patients with insomnia, and suggest its broad clinical relevance as a therapeutic option to treat insomnia.
